相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
Uday Kulkarni et al.
CANCER MEDICINE (2020)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2019)
Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide
Masamitsu Yanada et al.
LEUKEMIA & LYMPHOMA (2017)
Autologous transplant remains the preferred therapy for relapsed APL in CR2
C. Ganzel et al.
BONE MARROW TRANSPLANTATION (2016)
Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel
Oussama Abla et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
V. Madan et al.
LEUKEMIA (2016)
Targeted Therapy Alone for Acute Promyelocytic Leukemia
Francesco Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
Ezhilarasi Chendamarai et al.
PLOS ONE (2015)
Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission
Jennifer L. Holter Chakrabarty et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Resistance to Therapy in Acute Promyelocytic Leukemia
Jacqueline Lehmann-Che et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Hong-Hu Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies
Jin Lu et al.
ONCOLOGY LETTERS (2014)
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
Masamitsu Yanada et al.
BLOOD (2013)
Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
Naveen Pemmaraju et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy
Ezhilarasi Chendamarai et al.
BLOOD (2012)
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment
Emi Goto et al.
BLOOD (2011)
Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
Vikram Mathews et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide-Based Regimen
Rajasekar Thirugnanam et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Treatment of relapsed or refractory acute promyelocytic leukemia
Martin S. Tallman
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
V Mathews et al.
BLOOD (2006)
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
SL Soignet et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
